Valerio Therapeutics (XPAR:ALVIO) 3-Year EBITDA Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Valerio Therapeutics 3-Year EBITDA Growth Rate?

Valerio Therapeutics's EBITDA per Share for the six months ended in Dec. 2023 was €-0.05.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Valerio Therapeutics was 65.80% per year. The lowest was -134.00% per year. And the median was 12.55% per year.

Competitive Comparison of Valerio Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Valerio Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valerio Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Valerio Therapeutics's 3-Year EBITDA Growth Rate falls into.

Valerio Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Valerio Therapeutics (XPAR:ALVIO) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Valerio Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Valerio Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Valerio Therapeutics (XPAR:ALVIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (XPAR:ALVIO) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

C4X:Germany

Address

49 Boulevard du General, Martial Valin, Paris, FRA, 75015

Website

https://www.valeriotx.com

Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Valerio Therapeutics (XPAR:ALVIO) Headlines

No Headlines